4D Molecular Therapeutics, Inc. · NASDAQ:FDMT
4D Molecular Therapeutics — Clinical Trials at the Summit (June 2024)
10 slides from 4D Molecular Therapeutics's conference presentation, Jun 6, 2024
Slide 1: 24-week Results from the Randomized Phase 2 Dose Expansion Stage of the PRISM Trial
24-week Results from the Randomized Phase 2 Dose Expansion Stage of the PRISM Trial Evaluating 4D-150 in High Need nAMD Patients: Injection-free Patient Analyses Carl J. Danzig, M.D. Rand Eye Institute Deerfield Beach, FL © 2023 4D Molecular © 2023 4DTherapeutics. Molecular Therapeutics. All Rights
Slide 2: Disclosures
Disclosures Research Grant: Adverum, Alexion, Aviceda, Bayer, Cognition, Curacle, 4DMT, Genentech, Gyroscope, IvericBio/Astellas, Kodiak, Novartis, Regeneron, RegenxBio, Rezolute, Roche, Unity Consultant: Abbvie, Adverum, Alimera, Genentech, IvericBio/Astellas, Kodiak, Novartis, Ocuphire, Regeneron,
Slide 3: 4D-150 Dual-Transgene Intravitreal Gene Therapy
4D-150 Dual-Transgene Intravitreal Gene Therapy ▪ Primate-evolved intravitreal R100 capsid carrying a dual-transgene payload VEGF-C RNAi o Aflibercept & VEGF-C RNAi 4D-150 ▪ Single-dose intravitreal administration Aflibercept (VEGF Trap) DNA RNA transcription ▪ Widespread delivery to all major regio
Slide 4: PRISM Met All Objectives in wAMD Patients with Severe Disease Activity & High Anti-VEGF Treatment Burden
PRISM Met All Objectives in wAMD Patients with Severe Disease Activity & High Anti-VEGF Treatment Burden* Reduced Anatomical Durable Administration Safety Injection Burden Control Clinical Activity Single clinically Favorable 4D-150 (3E10 vg/eye)† 4D-150 (3E10 vg/eye)† Multi-year routine intravit
Slide 5: Ophthalmic Examination in 4D-150 Treated Patients
Ophthalmic Examination in 4D-150 Treated Patients No Clinically Significant or Recurrent Intraocular Inflammation* Anterior Chamber Cells* Vitreous Cells* Topical corticosteroid taper None Missed visit 4D-150 Trace Early termination† 3x1010 vg/eye 1+ (n=20) 2+ 3+ 4+ 1+ PC ▪ 97% (38 of 39) completed
Slide 6: Best Corrected Visual Acuity: Supplemental Injection-free
Best Corrected Visual Acuity: Supplemental Injection-free Stable Visual Acuity Equivalent to Standard Aflibercept Through Week 24 in Injection-free Participants 30 Average difference (95% CI) vs. Aflibercept Total Aflibercept(n=10) Aflibercept 2 mg Q8W (n=10) Adjusted mean (95% CI) change in ETDRS l
Slide 7: Best Corrected Visual Acuity By Supplemental Injection Status
Best Corrected Visual Acuity By Supplemental Injection Status Stable Visual Acuity Equivalent to Standard Aflibercept Through Week 24 in Both 4D-150 Dose Groups 30 Average difference (95% CI) vs. Aflibercept Supplemental Aflibercept(n=10) Aflibercept 2 mg Q8W (n=10) Adjusted mean (95% CI) change in
Slide 8: Central Subfield Thickness (CST): Supplemental Injection-free
Central Subfield Thickness (CST): Supplemental Injection-free 4D-150 3x1010 vg/eye: Sustained Reduction in CST and Reduced CST Fluctuation Compared to Aflibercept Average difference (95% CI) vs. Aflibercept 200 Total 150 Aflibercept(n=10) Aflibercept 2 mg Q8W (n=10) 4D-150 (3x1010 vg/eye) –8.3 (–92.
Slide 9: Central Subfield Thickness (CST): +/- Supplemental Injection
Central Subfield Thickness (CST): +/- Supplemental Injection 4D-150 3x1010 vg/eye: Reduced CST Fluctuation Compared to Aflibercept 200 Average difference (95% CI) vs. Aflibercept Supplemental Aflibercept 2(n=10) Aflibercept mg Q8W (n=10) 4D-150 (3x1010 vg/eye) –30.8 (–125, 63.2) 150 Adjusted mean (9
Slide 10: Conclusion: Promising Clinical Outcomes in Participants with Severe Disease Activity and High Treatment Burden
Conclusion: Promising Clinical Outcomes in Participants with Severe Disease Activity and High Treatment Burden ▪ 4D-150 was safe and well tolerated (through Week 24) o No clinically significant or recurrent intraocular inflammation o No patients restarted steroids through up to 48 weeks of follow-up
4D Molecular Therapeutics — Clinical Trials at the Summit (June 2024) on 6ix